Phase 3 COPD Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People who are 18 years of age or older at the time of joining the trial.
• People who are planning to receive a stem cell transplant from a donor (called an allogeneic transplant) for one of the following blood cancers: certain types of acute or chronic leukemia with very few or no abnormal cells present; certain types of myelodysplasia or a related condition with low numbers of abnormal cells present; or certain types of lymphoma (including follicular, Hodgkin, diffuse large B cell, mantle cell, peripheral T-cell, angioimmunoblastic T-cell, or anaplastic large cell lymphoma).
• People whose transplant plan involves a lower-intensity preparation treatment (called non-myeloablative or reduced intensity conditioning).
• People who have a suitable matched stem cell donor — either a matched family member (such as a sibling, parent, or child) or an unrelated matched donor through a donor registry — who is willing and medically able to donate blood stem cells.
• People whose heart is pumping well enough, with the heart's pumping strength (left ventricular ejection fraction) measured at 45% or higher.
• People whose kidneys are functioning well enough, as measured by a specific formula used to estimate kidney filtration rate (confirm with trial site for exact value).
• People whose lungs are functioning well enough, based on two specific breathing tests meeting minimum thresholds (confirm with trial site for exact values).
• People whose liver function blood test results are within acceptable ranges as defined by the trial.
• People who have a performance score of at least 60% on a standard scale used to measure how well a person can carry out daily activities (Karnofsky Performance Score).
• Women who are able to become pregnant must agree to use two effective methods of contraception at the same time, or to completely avoid heterosexual intercourse, from the time of signing the consent form until 15 months after the transplant.
• Men who have partners who could become pregnant must agree to use effective barrier contraception or to completely avoid heterosexual intercourse from the time of signing the consent form until 15 months after the transplant.
• People who plan to use certain approved maintenance medications after the transplant must disclose this at enrollment, and that plan must continue regardless of which treatment group the person is placed in — investigational maintenance drugs or certain chemotherapy-type maintenance drugs are not permitted.
• People who give their voluntary written consent to participate before any study-related procedures begin.

Who may not be able to join:

• People who have previously had a donor stem cell transplant.
• People whose cancer has spread to the central nervous system (brain or spinal cord).
• People whose acute myeloid leukemia (AML) developed from certain blood disorders called myeloproliferative neoplasms, or from overlap syndromes such as CMML or MDS/MPN (note: AML arising from myelodysplastic neoplasm is allowed — confirm with trial site).
• People who have a specific type of bone marrow scarring condition (myelofibrosis) that is primary or developed from Essential Thrombocythemia or Polycythemia Vera.
• People who have a bacterial, viral, or fungal infection that is not under control at the time of joining the trial.
• People who have active or inadequately treated tuberculosis (TB).
• People who have a significant build-up of fluid in the abdomen, chest, or around the heart that could interfere with one of the study medications.
• People who are HIV-positive with a detectable level of the virus in their blood (those with HIV but an undetectable viral load while on treatment may still be eligible — confirm with trial site).
• People who have hepatitis B or hepatitis C that is not controlled (those with hepatitis B or C with undetectable virus levels while on appropriate treatment may still be eligible — confirm with trial site).
• People who have had a blood clot in a vein or artery (such as a deep vein clot, pulmonary embolism, stroke, or heart attack) within the 6 months before joining, or who have severe heart failure or other serious uncontrolled heart conditions (note: blood clots related to a medical catheter are not automatically disqualifying — confirm with trial site).
• People who are pregnant or breastfeeding.
• People who have a serious medical or mental health condition that is likely to make it difficult to participate in the trial.
• People who have had another cancer in the past, unless it was a certain type of treated skin cancer or treated early-stage cervical cancer, or a cancer that was fully treated with curative intent 5 or more years ago (cancers treated less than 5 years ago require review and approval by the trial leadership).
• People whose transplant preparation plan includes certain immune-suppressing medications called ATG or alemtuzumab.
• People for whom infusions of donor immune cells (donor leukocyte infusions) are planned after the transplant.
• People who have previously been treated with a medication called ruxolitinib.
• People who have received certain immune checkpoint therapy drugs within 6 months before starting the transplant preparation.
• People with a partially matched (7 out of 8) donor who have antibodies directed against that donor, or who would require special desensitization treatment.
• People who are taking part in another trial involving an experimental medication (one with no approved uses by major regulatory bodies) at the same time as this study.

Important: Always verify eligibility with the trial site directly before applying.